Ascidian Therapeutics
Boston
About Ascidian Therapeutics
Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $90.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2023)
- Website: ascidian-tx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Genetics, Medical, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ascidian-therapeutics-75545 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.